ENZON PHARM (EZ1.SG)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon… Read more
Market Cap & Net Worth: ENZON PHARM (EZ1.SG) (EZ1)
ENZON PHARM (EZ1.SG) (STU:EZ1) has a market capitalization of $3.62 Million (€3.53 Million) as of March 18, 2026. Listed on the STU stock exchange, this Germany-based company holds position #35123 globally and #4119 in its home market, demonstrating a 9400.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENZON PHARM (EZ1.SG)'s stock price €0.05 by its total outstanding shares 74214603 (74.21 Million).
ENZON PHARM (EZ1.SG) Market Cap History: 2015 to 2026
ENZON PHARM (EZ1.SG)'s market capitalization history from 2015 to 2026. Data shows change from $13.10 Million to $3.62 Million (-11.33% CAGR).
ENZON PHARM (EZ1.SG) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENZON PHARM (EZ1.SG)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
357.46x
ENZON PHARM (EZ1.SG)'s market cap is 357.46 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
11.95x
ENZON PHARM (EZ1.SG)'s market cap is 11.95 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.14 Million | $8.38 Million | -$1.13 Million | 1.21x | N/A |
| 2017 | $11.09 Million | $8.38 Million | $5.45 Million | 1.32x | 2.04x |
| 2018 | $11.27 Million | $6.92 Million | $5.85 Million | 1.63x | 1.93x |
| 2019 | $11.73 Million | $207.00K | -$979.00K | 56.67x | N/A |
| 2020 | $13.48 Million | $52.00K | -$1.31 Million | 259.30x | N/A |
| 2021 | $20.72 Million | $701.00K | -$469.00K | 29.56x | N/A |
| 2022 | $16.15 Million | $26.00K | -$186.00K | 621.15x | N/A |
| 2024 | $9.29 Million | $26.00K | $778.00K | 357.46x | 11.95x |
Competitor Companies of EZ1 by Market Capitalization
Companies near ENZON PHARM (EZ1.SG) in the global market cap rankings as of March 18, 2026.
Key companies related to ENZON PHARM (EZ1.SG) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ENZON PHARM (EZ1.SG) Historical Marketcap From 2015 to 2026
Between 2015 and today, ENZON PHARM (EZ1.SG)'s market cap moved from $13.10 Million to $ 3.62 Million, with a yearly change of -11.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.62 Million | +72.73% |
| 2025 | €2.09 Million | -77.46% |
| 2024 | €9.29 Million | +73.05% |
| 2023 | €5.37 Million | -66.75% |
| 2022 | €16.15 Million | -22.06% |
| 2021 | €20.72 Million | +53.67% |
| 2020 | €13.48 Million | +14.94% |
| 2019 | €11.73 Million | +4.12% |
| 2018 | €11.27 Million | +1.58% |
| 2017 | €11.09 Million | +9.39% |
| 2016 | €10.14 Million | -22.62% |
| 2015 | €13.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ENZON PHARM (EZ1.SG) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.62 Million USD |
| MoneyControl | $3.62 Million USD |
| MarketWatch | $3.62 Million USD |
| marketcap.company | $3.62 Million USD |
| Reuters | $3.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.